Methyl aminolevulinate

Methyl aminolevulinate
Clinical data
AHFS/Drugs.com	Multum Consumer Information
ATC code	L01XD03 (WHO) ;
Identifiers
	IUPAC name Methyl 5-amino-4-oxopentanoate;
CAS Number	33320-16-0 ;
PubChem CID	157922;
DrugBank	DB00992 ;
ChemSpider	13180320 ;
UNII	585NM85KYM;
ChEMBL	ChEMBL1096562 ;
CompTox Dashboard (EPA)	DTXSID3048570 ;
Chemical and physical data
Formula	C6H11NO3
Molar mass	145.158 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(CC(N)C(=O)OC)C;
	InChI InChI=1S/C6H11NO3/c1-4(8)3-5(7)6(9)10-2/h5H,3,7H2,1-2H3 ; Key:FLQHIIVXMKXKFT-UHFFFAOYSA-N ;
	(what is this?) (verify)

Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.

Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.

Metvix is developed by Photocure and Galderma has bought all rights to Metvix.^[1]

^ "Photocure Divests Metvix to Galderma for EUR 51 Million". Archived from the original on 2011-02-07. Retrieved 2010-09-10.

[1] "Photocure Divests Metvix to Galderma for EUR 51 Million". Archived from the original on 2011-02-07. Retrieved 2010-09-10.

[1]